Use of real-world evidence in the U.S. Food and Drug Administration and the European Medicines Agency approvals of oncology products supported by single-arm trials (2022-2025).
- DOI
- 10.1093/oncolo/oyag296
- Published
- 2026 Aug 6
- Container
- The oncologist
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/oncolo/oyag296,
title = {Use of real-world evidence in the U.S. Food and Drug Administration and the European Medicines Agency approvals of oncology products supported by single-arm trials (2022-2025).},
author = {Su L and Chen L and Mamtani R and Betigeri S and Hubbard R and Burcu M},
year = {2026},
journal = {The oncologist},
doi = {10.1093/oncolo/oyag296},
url = {https://doi.org/10.1093/oncolo/oyag296}
}RIS
TY - JOUR TI - Use of real-world evidence in the U.S. Food and Drug Administration and the European Medicines Agency approvals of oncology products supported by single-arm trials (2022-2025). AU - Su L AU - Chen L AU - Mamtani R AU - Betigeri S AU - Hubbard R AU - Burcu M PY - 2026 JO - The oncologist DO - 10.1093/oncolo/oyag296 UR - https://doi.org/10.1093/oncolo/oyag296 ER -
APA
L, S., L, C., R, M., S, B., R, H., & M, B. (2026). Use of real-world evidence in the U.S. Food and Drug Administration and the European Medicines Agency approvals of oncology products supported by single-arm trials (2022-2025).. The oncologist. https://doi.org/10.1093/oncolo/oyag296
Source records
- pubmed · retrieved 2026-09-24T18:50:48.691Z
- europe-pmc · retrieved 2026-09-24T18:50:48.707Z